CN105535532A - Medicinal composition for treating community-acquired pneumonia - Google Patents
Medicinal composition for treating community-acquired pneumonia Download PDFInfo
- Publication number
- CN105535532A CN105535532A CN201511001716.4A CN201511001716A CN105535532A CN 105535532 A CN105535532 A CN 105535532A CN 201511001716 A CN201511001716 A CN 201511001716A CN 105535532 A CN105535532 A CN 105535532A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- acquired pneumonia
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and relates to a medicinal composition for treating community-acquired pneumonia. The medicinal composition is prepared from the following raw materials in parts by weight: folium mori, fresh rehmannia root, thorny elaeagnus leaf, bulbus fritillariae cirrhosae, semen raphanin, the root of straight ladybell, herb of Tibet lancea, dwarf lilyturf tuber, henry clematis root, herba dendrobii, ginseng and licorice root. The medicinal composition follows the prescription formulating rule of monarch, minister, assistant and guide, is proper in medication, rigorous in compatibility, and distinct in primary drug and secondary drug; the raw materials mutually gain; the medicinal composition for treating the community-acquired pneumonia can be used for relieving cough and asthma, clearing heat and moistening lung and supplementing Qi and strengthening the body, and has the advantages of high pertinency, significant effect and high cure rate.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of community acquired pneumonia.
Background technology
Community acquired pneumonia, refers to infectious pulmonary parenchyma (containing alveolar wall, the i.e. sensu lato interstitial lung) inflammation of urging trouble outside hospital, comprises and has clearly preclinical pathogenic infection and the pneumonia of falling ill in incubation period after people institute.CAP is one of Common infectious diseases threatening human health, and its pathogenic former composition and resistant characterization also exist notable difference between country variant, different regions, and As time goes on and constantly change.
In recent years, due to the aging of social population, immune impairment host increase, the reason such as pathogen transition and the rising of antibiotics resistance rate, community acquired pneumonia control the Liao Dynasty face many new between topic.Chinese medicine demonstrates huge advantage improving symptom and sign, Shorten the Treatment Process and improve in overall treatment effect, and the Chinese medicine composition for this reason studying effective treatment community acquired pneumonia is very necessary.
The patent of invention of disclosed treatment community acquired pneumonia has a lot at present, such as: Chinese invention patent application: 201410822536.1 disclose the purposes of a kind of pharmaceutical composition in preparation treatment community acquired pneumonia medicine, this pharmaceutical composition comprises Radix Pseudostellariae, the Radix Astragali, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Rhizoma Gymnadeniae, Radix Rehmanniae Preparata, Radix Trichosanthis, Radix Scutellariae, Herba Hedyotidis Diffusae, Radix Glycyrrhizae raw materials, but the existing pharmaceutical composition suitability is more single, the course for the treatment of is longer, it is not obvious to take effect.
Summary of the invention
The object of the invention is to overcome weak point of the prior art, there is provided that a kind of suitability is wide, the pharmaceutical composition of instant effect short treating period, treatment community acquired pneumonia easy to use, it has clearing heat and moistening lung, the effects such as relieving cough and asthma, also there is good effect, the advantages such as side effect is low, taking convenience.In addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use preparation under the prerequisite ensureing curative effect by this Chinese medicine composition.
The object of the invention is to be achieved through the following technical solutions: a kind of pharmaceutical composition for the treatment of community acquired pneumonia, described pharmaceutical composition comprises the raw materials of following parts by weight: Folium Mori 10-20 part, Radix Rehmanniae 9-15 part, Folium Elaeagni 8-15 part, Bulbus Fritillariae Cirrhosae 8-12 part, Semen Raphani 6-12 part, Radix Adenophorae (Radix Glehniae) 3-10 part, Herba Lanceae Tibeticae 3-10 part, Radix Ophiopogonis 3-8 part, Radix Clematidis Henryi 3-8 part, Herba Dendrobii 3-6 part, Radix Ginseng 2-6 part and Radix Glycyrrhizae 1-10 part.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: 10 parts, Folium Mori, Radix Rehmanniae 9 parts, Folium Elaeagni 8 parts, Bulbus Fritillariae Cirrhosae 8 parts, Semen Raphani 6 parts, Radix Adenophorae (Radix Glehniae) 3 parts, Herba Lanceae Tibeticae 3 parts, Radix Ophiopogonis 3 parts, Radix Clematidis Henryi 3 parts, Herba Dendrobii 3 parts, Radix Ginseng 2 parts and 1 part, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: 15 parts, Folium Mori, Radix Rehmanniae 12 parts, Folium Elaeagni 12 parts, Bulbus Fritillariae Cirrhosae 10 parts, Semen Raphani 9 parts, Radix Adenophorae (Radix Glehniae) 6 parts, Herba Lanceae Tibeticae 6 parts, Radix Ophiopogonis 5 parts, Radix Clematidis Henryi 5 parts, Herba Dendrobii 4 parts, Radix Ginseng 4 parts and 5 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition comprises the raw materials of following parts by weight: 20 parts, Folium Mori, Radix Rehmanniae 15 parts, Folium Elaeagni 15 parts, Bulbus Fritillariae Cirrhosae 12 parts, Semen Raphani 12 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Herba Lanceae Tibeticae 10 parts, Radix Ophiopogonis 8 parts, Radix Clematidis Henryi 8 parts, Herba Dendrobii 6 parts, Radix Ginseng 6 parts and 10 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made into capsule, tablet or granule.
Correspondingly, present invention also offers a kind of preparation method of pharmaceutical composition of described treatment community acquired pneumonia, comprise the following steps:
S1: get Folium Mori, washes away impurity, 50 DEG C of hot air dryings 5 hours, control moisture is 3-8%, pulverizes, and crosses 40-60 mesh sieve, obtain coarse powder, coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, micronizing is carried out respectively after drying, cross 800 mesh sieves, obtain Ultra-fine Powder of Mulberry Leaves, for subsequent use;
S2: get Radix Rehmanniae, Folium Elaeagni, Bulbus Fritillariae Cirrhosae, Semen Raphani, Radix Adenophorae (Radix Glehniae), Herba Lanceae Tibeticae, Radix Ophiopogonis, Radix Clematidis Henryi, Herba Dendrobii, Radix Ginseng and Radix Glycyrrhizae, add the distilled water immersion 3-8 hour of medical material total amount 3-7 times weight, boil 3-5 hour, filter, obtain filtrate and filtering residue, in filtering residue, add the purified water of initial medical material 3-6 times weight, boil 1-3 hour, filter and obtain filtrate and preserve filtering residue, merge twice filtrate, concentrated, obtaining detecting relative density at 65 DEG C is the extractum A of 1.10-1.25, for subsequent use;
S3: the ethanol adding the concentration 60-75% of 3-7 times of weight in the filtering residue of S2, reflux, extract, 1-2 time, each 3-6 hour, filters, merging filtrate, and distilling under reduced pressure removing ethanol is also concentrated, obtains the extractum B that 65 DEG C of relative densities are 1.15-1.25, for subsequent use;
S4: described extractum A mixed homogeneously with described extractum B, drying under reduced pressure, pulverizes, and crosses 100-200 mesh sieve, mixes with Ultra-fine Powder of Mulberry Leaves, adds adjuvant, utilizes modern general Chinese medicine preparation technology to make the finished product preparation of clinical needs.
Source, the nature and flavor of Chinese prescription of the present invention Chinese crude drug used, return through and effect:
Folium Mori: this product is the dried leaves of moraceae plants Mulberry; Nature and flavor are sweet, bitter, cold; Return lung, Liver Channel; Dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, liver heat removing and eyesight improving.
Radix Rehmanniae: this product is the fresh rhizome of scrophulariaceae rehmannia glutinosa plant; Sweet in the mouth, hardship, cold in nature; Enter the heart, liver, kidney channel; Heat clearing away, removing heat from blood, promotes the production of body fluid.
Folium Elaeagni: this product is the blade of Elaeangnaceae plant Fructus Elaeagni; Nature and flavor acid, tepor; Return lung meridian; Relieving cough and asthma, hemostasis, removing toxic substances.
Bulbus Fritillariae Cirrhosae: this product is the dry bulb of liliaceous plant Bulbus Fritillariae Cirrhosae, Fritillaria unibracteata, Gansu Bulbus Fritillariae Uninbracteatae or Bulbus Fritillariae cirrhosae; Nature and flavor are bitter, sweet, are slightly cold; Return lung, heart channel; Clearing heat and moistening lung, preventing phlegm from forming and stopping coughing.
Semen Raphani: this product is the dry mature seed of crucifer Radix Raphani; Nature and flavor are pungent, sweet, flat; Return lung, spleen, stomach warp; Help digestion de-swelling, lowering the adverse-rising QI to resolve phlegm.
Radix Adenophorae (Radix Glehniae): this product is campanulaceae Lady bell plant four leaf Radix Adenophorae (Radix Glehniae), Folium Pruni Radix Adenophorae (Radix Glehniae) or its congener, is used as medicine with root; Nature and flavor are sweet, cool; Return lung; Stomach warp; Clearing away heat and nourishing YIN, nourishing the lung to arrest cough.
Herba Lanceae Tibeticae: this product is the herb of Scrophulariaceae Herba Lanceae Tibeticae platymiscium Herba Lanceae Tibeticae; Nature and flavor are sweet, bitter, cold; Return lung, the warp such as stomach, large intestine; Lung heat clearing, eliminates the phlegm, removing toxic substances.
Radix Ophiopogonis: this product is the tuber of liliaceous plant dwarf lilyturf; Sweet micro-hardship, cold; Enter lung, stomach, heart channel; Nourishing YIN and moistening the lung, clear away heart-fire relieving restlessness, reinforcing stomach reg fluid.
Radix Clematidis Henryi: this product is root or the leaf of cohosh henry clematis; Acrid in the mouth, hardship, cool in nature; GUIXIN, lung, stomach warp; Heat-clearing and toxic substances removing, eliminating phlegm and relieving cough, promoting flow of QI and blood, pain relieving.
Herba Dendrobii: this product is the fresh or dry stem of orchid dendrobium loddigesii Rolfe, Herba Dendrobii oculati, HERBA DENDROBII, Herba Dendrobii or Dendrobium nobile; Property slightly sweet flavor micro-salty, cold; Enter stomach, lung, kidney channel; Promote the production of body fluid stomach reinforcing, nourishing YIN and clearing away heat, lung moistening kidney tonifying, the strong waist of improving eyesight.
Radix Ginseng: this product is the dry root of Araliaceae Radix Ginseng; Sweet in the mouth, micro-hardship, property is put down; Return spleen, lung, heart channel; Strongly invigorating primordial QI, multiple arteries and veins takes off admittedly, and invigorating the spleen to benefit the lung, promotes the production of body fluid, and calms the nerves.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Nature and flavor are sweet, flat; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of Chinese prescription of the present invention: Chinese prescription of the present invention is with Folium Mori and Radix Rehmanniae for monarch drug, and cold expelling stops blooding, and clearing away heat-fire, promotes the production of body fluid and moisturize, and plays primary treatment effect to community acquired pneumonia; With Folium Elaeagni, Bulbus Fritillariae Cirrhosae, Semen Raphani for ministerial drug, wherein, Folium Elaeagni, the Bulbus Fritillariae Cirrhosae property of medicine are gentle, return lung meridian, clearing heat and moistening lung, relieving cough and asthma, and auxiliary monarch drug promotes treatment community acquired pneumonia symptom; The Semen Raphani property of medicine is gentle, returns lung meridian, prevention community acquired pneumonia subsequent symptom; With Radix Adenophorae (Radix Glehniae), Herba Lanceae Tibeticae, Radix Ophiopogonis, Radix Clematidis Henryi, Herba Dendrobii for adjuvant drug, wherein, Radix Adenophorae (Radix Glehniae), Herba Lanceae Tibeticae, Radix Ophiopogonis nourishing YIN and moistening the lung, nourishing the lung to arrest cough, assist monarch, ministerial drug reinforcement treatment community acquired pneumonia, Radix Clematidis Henryi, Herba Dendrobii, Concretio Silicea Bambusae clear heat and eliminate phlegm, treatment such as cough is more than waits subsequent symptom; With Radix Ginseng and Radix Glycyrrhizae for making medicine, be coordinating the actions of various ingredients in a prescription drug effect.The each medicine of prescription interacts, and mutually circulates, mutually promotes, and strengthens the drug effect for the treatment of community acquired pneumonia.Pharmaceutical composition prescription of the present invention follows monarch, minister, the square gauge processed rule of helping, making, and medication is suitable for, and compatibility is rigorous, makes a distinction between the important and the lesser one, just and the state of an illness.
Therefore, the present invention also asks to protect the application of aforementioned pharmaceutical compositions in preparation treatment community acquired pneumonia medicine.
Compared to the prior art the present invention, has following technical advantage:
1, the present invention treats the pharmaceutical composition of community acquired pneumonia, plays the effect of Chinese medicine Coryza Treated by Syndrome Differentiation, and medication is suitable for, and compatibility is rigorous, makes a distinction between the important and the lesser one, the proper and state of an illness, wide to the suitability of community acquired pneumonia.
2, the present invention treats the pharmaceutical composition of community acquired pneumonia, and soon effective, cure rate is high, short treating period.
3, the present invention treats the pharmaceutical composition of community acquired pneumonia, and medication is simplified, and dosage is few, and medical material is all listed by Chinese Pharmacopoeia, and source is wide, cost is low.
4, the present invention treats the pharmaceutical composition of community acquired pneumonia, and preparation technology is simple, is applicable to suitability for industrialized production.
Detailed description of the invention:
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Embodiment 1
The embodiment of the present invention 1 pharmaceutical composition comprises the raw materials of following parts by weight: 10 parts, Folium Mori, Radix Rehmanniae 9 parts, Folium Elaeagni 8 parts, Bulbus Fritillariae Cirrhosae 8 parts, Semen Raphani 6 parts, Radix Adenophorae (Radix Glehniae) 3 parts, Herba Lanceae Tibeticae 3 parts, Radix Ophiopogonis 3 parts, Radix Clematidis Henryi 3 parts, Herba Dendrobii 3 parts, Radix Ginseng 2 parts and 1 part, Radix Glycyrrhizae.
Preparation method:
S1: get Folium Mori, washes away impurity, 50 DEG C of hot air dryings 5 hours, controlling moisture is 5%, pulverizes, and crosses 50 mesh sieves, obtain coarse powder, coarse powder is sucked air-stream type ultrafine pulverizer and carry out micronizing, pulverize pressure 0.5MPa, charging rate is 30mg/s, micronizing is carried out respectively after drying, cross 800 mesh sieves, obtain Ultra-fine Powder of Mulberry Leaves, for subsequent use;
S2: get Radix Rehmanniae, Folium Elaeagni, Bulbus Fritillariae Cirrhosae, Semen Raphani, Radix Adenophorae (Radix Glehniae), Herba Lanceae Tibeticae, Radix Ophiopogonis, Radix Clematidis Henryi, Herba Dendrobii, Radix Ginseng and Radix Glycyrrhizae, add the distilled water immersion 6 hours of medical material total amount 5 times of weight, boil 4 hours, filter, obtain filtrate and filtering residue, in filtering residue, add the purified water of initial medical material 4 times of weight, boil 3 hours, filter and obtain filtrate and preserve filtering residue, merge twice filtrate, concentrated, obtaining detecting relative density at 65 DEG C is the extractum A of 1.20, for subsequent use;
S3: the ethanol adding the concentration 75% of 5 times of weight in the filtering residue of S2, reflux, extract, 2 times, each 4 hours, filters, merging filtrate, and distilling under reduced pressure removing ethanol is also concentrated, obtains the extractum B that 65 DEG C of relative densities are 1.20, for subsequent use;
S4: described extractum A mixed homogeneously with described extractum B, drying under reduced pressure, pulverizes, and crosses 150 mesh sieves, mixes with Ultra-fine Powder of Mulberry Leaves, adds adjuvant, utilizes modern general Chinese medicine preparation technology to make the capsule of clinical needs.
Embodiment 2
The embodiment of the present invention 2 pharmaceutical composition comprises the raw materials of following parts by weight: 15 parts, Folium Mori, Radix Rehmanniae 12 parts, Folium Elaeagni 12 parts, Bulbus Fritillariae Cirrhosae 10 parts, Semen Raphani 9 parts, Radix Adenophorae (Radix Glehniae) 6 parts, Herba Lanceae Tibeticae 6 parts, Radix Ophiopogonis 5 parts, Radix Clematidis Henryi 5 parts, Herba Dendrobii 4 parts, Radix Ginseng 4 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is as embodiment 1.
Embodiment 3
The embodiment of the present invention 3 pharmaceutical composition comprises the raw materials of following parts by weight: 20 parts, Folium Mori, Radix Rehmanniae 15 parts, Folium Elaeagni 15 parts, Bulbus Fritillariae Cirrhosae 12 parts, Semen Raphani 12 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Herba Lanceae Tibeticae 10 parts, Radix Ophiopogonis 8 parts, Radix Clematidis Henryi 8 parts, Herba Dendrobii 6 parts, Radix Ginseng 6 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is as embodiment 1.
Pharmaceutical composition pharmacodynamic study of the present invention:
Test example one: pharmaceutical composition of the present invention is to the Therapy study of Diagnosis of Rats infected with M. Pneumonia animal model
1. test objective and method
Object: according to the requirement of " new Chinese medicine pharmaceutical research guide ", study the Pharmacodynamics of pharmaceutical composition of the present invention at treatment community acquired pneumonia, the capsule of the pharmaceutical composition of the present invention obtained by specific embodiment 1,2, to the rat model administration of community acquired pneumonia, observes pharmaceutical composition of the present invention to the impact of community acquired pneumonia.
Method: get 75 4-6 week SPF level male SD rat (buying from radiological study institute of the Chinese Academy of Medical Sciences), average weight 120-160g, all animals 3 grades of clean animal laboratory rearings 3 days to conform.Get wherein 50 rats and inoculate 00uL10 every day
6the mycoplasma pneumoniae pure culture of CFU/mL, vaccinization 4 days, above-mentioned 45 rats are divided into 4 groups at random, often organize 15, be respectively infected group, azithromycin group, the embodiment of the present invention 1 group, the embodiment of the present invention 2 groups, establish 15 rats to be set to Normal group in addition, often organize sub-cage rearing, 5, every cage.
Each group of process is as follows: infected group organizes identical feeding with other, does not do any drug treating; Azithromycin group subcutaneous injection every day azithromycin (l0mg/kg body weight), compound concentration is the azithromycin medicine of l0mg/mL, is dissolved in 50mL normal saline by 50Omg azithromycin injection; The capsule (l0mg/kg body weight, capsule physiological saline solution compounding pharmaceutical compositions final concentration is the drug solution of l0mg/mL) that medicine composite for curing group subcutaneous injection every day specific embodiment 1,2 of the present invention obtains; Normal group does not process to put to death immediately and makes pathological section scoring.
Drug treating later evaluation standard
Inoculate all the last time for each group and start process, put to death rat by relative medicine compositions-treated after 6 days continuously, after cutting thoracic cavity, through trachea to pulmonary injection 10% formalin, fixing lung tissue.After ligation trachea, take whole lung tissue (comprising complete left and right bronchus), immerse and fill in the clean container of 10% formalin, carry out histopathological scores.The community acquired pneumonia histopathological scores system being used for hamster is adopted to evaluate rat model.Adopt blind to mark to histopathology specimen, the histopathology worker namely marked does not know the source of tissue and comes from the equal randomization detection of whole tested slide of the pulmo of animal.This evaluation system is made up of the denumerable scoring of a 0-23 point of scope.In this marking system, respectively to often opening the chamber surrounding wetting of section and the bronchioles caused and bronchial number, the severity oozed out in the degree of tube chamber surrounding wetting, tube chamber, the degree of perivascular infiltration, the severity of desquamative pneumonia are marked, add up to integration, subsequently the scoring of every side lung is added divided by 2, obtains lung tissue disease's Neo-Confucianism scoring of each rat.
Histopathological scores system:
The percentage rate of A. peribronchiolar/bronchus infiltrating sites: 0=without; 1=a little (<25%); 2=many (25% one 75%); 3=owns (>75%)
B. it is qualitative that bronchioles/peribronchial infiltrates: O=without, accidental slight infiltration or peribronchial lymphoid cell agglomerate see intact animal; 1=is light, abnormal.Usually with the ring be interrupted; 2=moderate, complete ring or half moon-shaped ring, with the thickness of <5 cell; 3=is serious, and ring completely, with >5-10 cell thickness
C. bronchioles/bronchial lumen oozes out: 0=without; 1=is slight, and <25% chamber closes; 2=severe, >25% chamber closes
D. perivascular infiltration. (percentage rate at position): 0=is without, 1=few (<1O%); 2=many (10%-50%); 3=great majority (>50%)
E. desquamative pneumonia: 0=without; 1=is slight: plaque-like substance infiltrates; 2=severe: the substance that plaque-like melts platform infiltrates.
Last mark is A 10 (B ten C)+D+E, and every rat scoring often organized in record, and statistics group difference and the interior difference of group assess pharmaceutical composition drug effect of the present invention.
Antibacterial removes marking system:
Remove: patient is after terminating two courses for the treatment of, and the pathogen in its specimen is eliminated completely.
Part is removed: after patient treatment, its original pathogen has one to be eliminated.
Do not remove: after patient treatment terminates, previously pathogen is unchanged.
Replace: existing pathogen is eliminated, but have new pathogen to occur, and have clinical symptoms.
3. result is as table 1:
Table 1 different group histological scores results contrast
Note: compared with normal control ratio,
?p<0.01; Compared with infected group,
*p<0.01, compared with azithromycin group,
#p<0.05,
##p<0.01.
4. conclusion
Pharmaceutical composition of the present invention can improve the pathological characteristics of community acquired pneumonia rat model, and and then improve community acquired pneumonia associated conditions, compare azithromycin, the effect improving pneumonia associated pathology is more obvious.
Test two: pharmaceutical composition of the present invention is to the clinical observation on the therapeutic effect of community acquired pneumonia clinical volunteers patient
(1) physical data
Patient 150 example, man 75 example, female 75 example; Be divided into 3 groups at random, often organize 50 people, in age 20-60 year, 41 years old mean age, clarify a diagnosis as community acquired pneumonia.According to the standard that national health planning commission issues, community acquired pneumonia screening criteria is: 1. the cough recently occurred, expectoration or original symptoms of respiratory disease increase the weight of, and occur purulent sputum, accompanies or does not accompany chest pain; 2. generate heat; 3. pulmonary consolidation sign and (or) news and moist sound of trembling; 4.WBC>10x10
9individual/L or <4x10
9individual/L, companion or not companion cell shift to left; 5. chest X-ray display lamellar, patch shape wellability shade or chromic fibrous change, accompany or do not accompany hydrothorax.
In above 1-4 item, any 1 adds the 5th, and except pulmonary tuberculosis, lung tumors, non-infectious Interstitial Lung Disease, pulmonary edema, pulmonary atelectasis, pulmonary infarction, after pulmanory eosinophilia and pulmonary vasculitis etc., can clinical diagnosis be set up.
(2) Therapeutic Method
To the Chinese medicinal composition capsules preparation that patient adopts specific embodiment of the invention 1-3 to obtain, 2 times on the one, each 3 continuous 6 days is a course for the treatment of, uses 2 courses for the treatment of continuously and observes patients symptomatic each course for the treatment of.
(3) efficacy assessment standard
Recovery from illness: patient is after treatment, and its clinical symptoms, sign, etiological examination and lab testing recover normal all completely.
Effective: after patient treatment, its symptom and sign etc. is clearly better, but has one not yet to recover normal in four inspections.
Take a turn for the better: after patient treatment, clinical symptoms etc. take a turn for the better to some extent.
Invalid: patient is after treatment, and every inspection, without significant change, even increases the weight of.
Bacteria clearance:
Remove: patient is after terminating two courses for the treatment of, and the pathogen in its specimen is eliminated completely.
Part is removed: after patient treatment, its original pathogen has one to be eliminated.
Do not remove: after patient treatment terminates, previously pathogen is unchanged.
Replace: existing pathogen is eliminated, but have new pathogen to occur, and have clinical symptoms.
(4) therapeutic outcome is as following table.
Table 2 community acquired pneumonia clinical volunteers uses the statistical effect after 1 course for the treatment of of pharmaceutical composition of the present invention
Table 3 community acquired pneumonia clinical volunteers uses the statistical effect after 2 courses for the treatment of of pharmaceutical composition of the present invention
Table 4 community acquired pneumonia clinical volunteers uses the antibacterial after pharmaceutical composition of the present invention to remove result statistics
(5) conclusion
Can draw from table 2-4, pharmaceutical composition of the present invention has antiinflammatory lung moistening, removes effect of cause of disease, and with strong points, and short treating period, effectively can treat community acquired pneumonia.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (5)
1. treat the pharmaceutical composition of community acquired pneumonia for one kind, it is characterized in that, described pharmaceutical composition comprises the raw materials of following parts by weight: Folium Mori 10-20 part, Radix Rehmanniae 9-15 part, Folium Elaeagni 8-15 part, Bulbus Fritillariae Cirrhosae 8-12 part, Semen Raphani 6-12 part, Radix Adenophorae (Radix Glehniae) 3-10 part, Herba Lanceae Tibeticae 3-10 part, Radix Ophiopogonis 3-8 part, Radix Clematidis Henryi 3-8 part, Herba Dendrobii 3-6 part, Radix Ginseng 2-6 part and Radix Glycyrrhizae 1-10 part.
2. the pharmaceutical composition for the treatment of community acquired pneumonia as claimed in claim 1, it is characterized in that, described pharmaceutical composition comprises the raw materials of following parts by weight: 10 parts, Folium Mori, Radix Rehmanniae 9 parts, Folium Elaeagni 8 parts, Bulbus Fritillariae Cirrhosae 8 parts, Semen Raphani 6 parts, Radix Adenophorae (Radix Glehniae) 3 parts, Herba Lanceae Tibeticae 3 parts, Radix Ophiopogonis 3 parts, Radix Clematidis Henryi 3 parts, Herba Dendrobii 3 parts, Radix Ginseng 2 parts and 1 part, Radix Glycyrrhizae.
3. the pharmaceutical composition for the treatment of community acquired pneumonia as claimed in claim 1, it is characterized in that, described pharmaceutical composition comprises the raw materials of following parts by weight: 15 parts, Folium Mori, Radix Rehmanniae 12 parts, Folium Elaeagni 12 parts, Bulbus Fritillariae Cirrhosae 10 parts, Semen Raphani 9 parts, Radix Adenophorae (Radix Glehniae) 6 parts, Herba Lanceae Tibeticae 6 parts, Radix Ophiopogonis 5 parts, Radix Clematidis Henryi 5 parts, Herba Dendrobii 4 parts, Radix Ginseng 4 parts and 5 parts, Radix Glycyrrhizae.
4. the pharmaceutical composition for the treatment of community acquired pneumonia as claimed in claim 1, it is characterized in that, described pharmaceutical composition comprises the raw materials of following parts by weight: 20 parts, Folium Mori, Radix Rehmanniae 15 parts, Folium Elaeagni 15 parts, Bulbus Fritillariae Cirrhosae 12 parts, Semen Raphani 12 parts, Radix Adenophorae (Radix Glehniae) 10 parts, Herba Lanceae Tibeticae 10 parts, Radix Ophiopogonis 8 parts, Radix Clematidis Henryi 8 parts, Herba Dendrobii 6 parts, Radix Ginseng 6 parts and 10 parts, Radix Glycyrrhizae.
5. the pharmaceutical composition of the treatment community acquired pneumonia as described in any one of claim 1-4, is characterized in that: described pharmaceutical composition is made into capsule, tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511001716.4A CN105535532A (en) | 2015-12-29 | 2015-12-29 | Medicinal composition for treating community-acquired pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511001716.4A CN105535532A (en) | 2015-12-29 | 2015-12-29 | Medicinal composition for treating community-acquired pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535532A true CN105535532A (en) | 2016-05-04 |
Family
ID=55815434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511001716.4A Withdrawn CN105535532A (en) | 2015-12-29 | 2015-12-29 | Medicinal composition for treating community-acquired pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648492A (en) * | 2017-10-11 | 2018-02-02 | 郭锐翰 | Aid in nutritional agents of lung health and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712059A (en) * | 2005-05-23 | 2005-12-28 | 刘胜全 | Chinese medicine for treatig cavernous tuberculosis |
-
2015
- 2015-12-29 CN CN201511001716.4A patent/CN105535532A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712059A (en) * | 2005-05-23 | 2005-12-28 | 刘胜全 | Chinese medicine for treatig cavernous tuberculosis |
Non-Patent Citations (1)
| Title |
|---|
| 王冠华等: "王少华治疗肺病验案4则", 《河北中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648492A (en) * | 2017-10-11 | 2018-02-02 | 郭锐翰 | Aid in nutritional agents of lung health and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102475835A (en) | Pharmaceutical composition for treating common cold or cough caused by common cold in children and preparation method thereof | |
| CN105560884A (en) | Pharmaceutical composition for treating dog pneumonia and preparation method thereof | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| KR101474125B1 (en) | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
| CN101618146A (en) | Complex traditional Chinese medicine preparation for treating upper respiratory tract infection and preparation method thereof | |
| CN101628108A (en) | Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof | |
| CN104398595A (en) | Traditional Chinese medicine preparation used for treating silicosis, preparation method and application thereof | |
| CN102188689B (en) | Compound combination medicament for treating COPD, preparation method and application thereof | |
| CN103446414B (en) | Xiangmahanchuantie (XMHCT) and preparation technology | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN105535532A (en) | Medicinal composition for treating community-acquired pneumonia | |
| CN102552509A (en) | Traditional Chinese medicine combination for reducing heat and relieving cough | |
| CN113368198B (en) | Pharmaceutical composition for treating wind-heat affecting lung and preparation method and application thereof | |
| CN105434891A (en) | Method for preparing pharmaceutical composition for treating community-acquired pneumonia | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN103405722B (en) | Chinese herba preparation for preventing and treating infantile cough | |
| CN104096053A (en) | Medicine composition for treating infantile pneumonia | |
| CN112641871B (en) | Pharmaceutical composition for treating phlegm-heat accumulated in lung | |
| CN105687864A (en) | Artemisia leaf-containing pharmaceutical composition for treating community-acquired pneumonia | |
| CN112386671B (en) | Traditional Chinese medicine composition for treating interstitial lung disease and application thereof | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN108888731B (en) | Pharmaceutical composition for relieving cough and reducing sputum | |
| CN107510753B (en) | Traditional Chinese medicine composition for treating intractable hemoptysis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |
|
| WW01 | Invention patent application withdrawn after publication |